NASDAQ:CLDXCelldex Therapeutics Stock Price, Forecast & News

Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CLDX stock has increased by 32.0% and is now trading at $2.68. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Celldex Therapeutics.

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Celldex Therapeutics.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.71) by $0.02. The biopharmaceutical company had revenue of $2.73 million for the quarter, compared to analyst estimates of $1.28 million. Celldex Therapeutics had a negative return on equity of 47.60% and a negative net margin of 948.81%. View Celldex Therapeutics' earnings history.

Celldex Therapeutics's stock reverse split on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

2 Wall Street analysts have issued twelve-month price targets for Celldex Therapeutics' stock. Their forecasts range from $8.00 to $16.00. On average, they anticipate Celldex Therapeutics' share price to reach $12.00 in the next year. This suggests a possible upside of 347.8% from the stock's current price. View analysts' price targets for Celldex Therapeutics.

Press coverage about CLDX stock has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Celldex Therapeutics earned a news impact score of 1.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutCelldex Therapeutics.

Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), ACADIA Pharmaceuticals (ACAD), Precigen (PGEN), Micron Technology (MU), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), bluebird bio (BLUE) and Exelixis (EXEL).

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include TSP Capital Management Group LLC (2.33%) and Acadian Asset Management LLC (1.58%). Company insiders that own Celldex Therapeutics stock include James J Marino and Tibor Keler. View institutional ownership trends for Celldex Therapeutics.

CLDX stock was bought by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, and Acadian Asset Management LLC. Company insiders that have bought Celldex Therapeutics stock in the last two years include James J Marino, and Tibor Keler. View insider buying and selling activity for Celldex Therapeutics.

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLDX stock can currently be purchased for approximately $2.68.

Celldex Therapeutics has a market capitalization of $50.76 million and generates $3.57 million in revenue each year. The biopharmaceutical company earns $-50,880,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.

The official website for Celldex Therapeutics is www.celldex.com.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]